Abby Hardy, Author at BioTuesdays

Developments

Kane Biotech launches anti-biofilm shampoo at the Global Pet Expo

Kane Biotech (TSX-V:KNE) launched its silkstem anti-itch shampoo at the Global Pet Expo taking place on February 26-28, 2020 in Orlando, Florida. silkstem is a scientifically formulated anti-itch shampoo for dogs and...

February 26, 2020

Developments

FDA approves Baudax Bio’s ANJESO for pain

The FDA approved Baudax Bio’s (NASDAQ:BXRX) ANJESO for the management of moderate-to-severe pain, alone or in combination with other non-NSAID analgesics. ANJESO is a once-daily COX-2 preferential NSAID that is...

February 21, 2020

Developments

VBL Therapeutics launches Phase 2 metastatic colorectal cancer trial

VBL Therapeutics (NASDAQ:VBLT) launched a Phase 2 trial evaluating VB-111, in combination with nivolumab, for the treatment of metastatic colorectal cancer. VB-111, an adenovirus that carries a transgene for the Fas...

February 20, 2020

Developments

VistaGen reports positive results from Phase 2a major depressive disorder study

VistaGen Therapeutics (NASDAQ:VTGN) reported positive results from its Phase 2a clinical study of PH10 for treatment of major depressive disorder (MDD). PH10 is a synthetic neurosteroid nasal spray designed to activate...

February 20, 2020

Executive Moves

Renowned veterinarian, Dr. Jean Gauvin, joins Kane Biotech as chief veterinary officer

Jean Gauvin Kane Biotech (TSX-V:KNE) appointed renowned Canadian veterinarian, Dr. Jean Gauvin, as its chief veterinary officer. Dr. Gauvin will serve as a liaison between Kane Biotech and industry; guide the company’s...

February 20, 2020

Developments

Hepion’s CRV431 shows potential to impact multiple types of fibrotic disease

Hepion Pharmaceuticals (NASDAQ:HEPA) reported results from in vitro studies showing that CRV431 can decrease production of the extracellular matrix (ECM) molecules, collagen and fibronectin, from fibroblastic cells. The...

February 19, 2020

Developments

Five Prime misses primary endpoint in pancreatic cancer trial

Five Prime Therapeutics (NASDAQ:FPRX) reported that its Phase 2 trial evaluating cabiralizumab in combination with Opdivo, with and without chemotherapy, in patients with advanced pancreatic cancer failed to meet its...

February 18, 2020

Developments

Bellerophon reports positive topline data from Phase 2 INOpulse study

Bellerophon Therapeutics (NASDAQ:BLPH) reported positive top-line data from PHPF-002, a dose escalation, hemodynamics study of INOpulse for the treatment of pulmonary hypertension associated with pulmonary fibrosis. The...

February 18, 2020

Developments

Soligenix gets fast track designation for RiVax

The FDA granted fast track designation to Soligenix’s (NASDAQ:SNGX) RiVax for the prevention of ricin intoxication. Ricin is a lethal plant-derived toxin whose stability and high potency make it a potential biological...

February 13, 2020

Developments

Hepion advances to third dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the third dose level of CRV431 in its ongoing Phase 1 multiple ascending dose trial. The clinical trial management team determined the 150 mg dosing level to be safe and...

February 12, 2020

Author - Abby Hardy

Kane Biotech launches anti-biofilm shampoo at the Global Pet Expo

FDA approves Baudax Bio’s ANJESO for pain

VBL Therapeutics launches Phase 2 metastatic colorectal cancer trial

VistaGen reports positive results from Phase 2a major depressive disorder study

Renowned veterinarian, Dr. Jean Gauvin, joins Kane Biotech as chief veterinary officer

Hepion’s CRV431 shows potential to impact multiple types of fibrotic disease

Five Prime misses primary endpoint in pancreatic cancer trial

Bellerophon reports positive topline data from Phase 2 INOpulse study

Soligenix gets fast track designation for RiVax

Hepion advances to third dosing level in ongoing Phase 1 study of CRV431

Subscribe